Pancreatic Cancer Research

ResearcherCedars-Sinai Medical CenterActive in the last 2 years

Yi Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9861-4681; OpenAlex author ID A5100388089. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 15

  1. RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1↗
  2. Novel DZ-SIM Conjugate Targets Cancer Mitochondria and Prolongs Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/adtp.202200021↗
  3. RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression. Co-author DOI 10.1007/s13258-022-01217-0↗
  4. Mitochondrial-Associated Protein LRPPRC is Related With Poor Prognosis Potentially and Exerts as an Oncogene Via Maintaining Mitochondrial Function in Pancreat… Co-author DOI 10.3389/fgene.2021.817672↗
  5. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics13091493↗
  6. Long non‑coding RNA PCED1B‑AS1 promotes pancreatic ductal adenocarcinoma progression by regulating the miR‑411‑3p/HIF‑1α axis. Co-author DOI 10.3892/or.2021.8085↗
  7. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. Co-author DOI 10.3748/wjg.v26.i26.3737↗
  8. Effect of photodynamic therapy with (17R,18R)-2-(1-hexyloxyethyl)-2-devinyl chlorine E6 trisodium salt on pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.3748/wjg.v24.i46.5246↗
  9. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Co-author DOI 10.18632/oncotarget.17999↗
  10. Methylation of BNIP3 in pancreatic cancer inhibits the induction of mitochondrial-mediated tumor cell apoptosis. Co-author DOI 10.18632/oncotarget.18736↗
  11. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0298-y↗
  12. CdSe/ZnS quantum dots induce photodynamic effects and cytotoxicity in pancreatic cancer cells. Co-author DOI 10.3748/wjg.v22.i21.5012↗
  13. NEAT1 regulates pancreatic cancer cell growth, invasion and migration though mircroRNA-335-5p/c-met axis. First author PMID 27822425↗
  14. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2015.06.074↗
  15. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Co-author DOI 10.1097/mpa.0000000000000055↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dechun Li · 5 shared papers, 2015–2022 · strength 0.39
  2. Jian Zhou · 5 shared papers, 2015–2022 · strength 0.39
  3. Jian Yang · 4 shared papers, 2016–2022 · strength 0.34
  4. Leiming Xu · 4 shared papers, 2016–2020 · strength 0.31
  5. Bole Tian · 2 shared papers, 2021–2025 · strength 0.30
  6. Chang Chen · 1 shared paper, 2021 · strength 0.22
  7. Dongming Zhu · 3 shared papers, 2016–2017 · strength 0.20
  8. Fang Zhen Sun · 2 shared papers, 2018–2020 · strength 0.19
  9. Nannan Zheng · 2 shared papers, 2018–2020 · strength 0.19
  10. Jia Cao · 3 shared papers, 2016–2018 · strength 0.19
  11. Dongming Zhu · 2 shared papers, 2015–2022 · strength 0.18
  12. Chengjian Zhao · 1 shared paper, 2025 · strength 0.16
  13. Xiaoying Li · 1 shared paper, 2025 · strength 0.16
  14. Zixing Huang · 1 shared paper, 2025 · strength 0.16
  15. Chen Chang · 1 shared paper, 2025 · strength 0.16
  16. Junjie Xiong · 1 shared paper, 2025 · strength 0.16
  17. Yi Cheng · 1 shared paper, 2025 · strength 0.16
  18. Ke Cheng · 1 shared paper, 2025 · strength 0.16
  19. Huanji Xu · 1 shared paper, 2025 · strength 0.16
  20. Dan Cao · 1 shared paper, 2025 · strength 0.16
  21. Xiaorui Zhu · 1 shared paper, 2025 · strength 0.16
  22. Rui Wang · 1 shared paper, 2025 · strength 0.16
  23. Qingqing Leng · 1 shared paper, 2025 · strength 0.16
  24. Wanting Hou · 1 shared paper, 2025 · strength 0.16
  25. Chenyan Zhang · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.